Micro-light-emitting diodes(micro-LEDs)with outstanding performance are promising candidates for next-generation displays.To achieve the application of high-resolution displays such as meta-displays,virtual reality,an...Micro-light-emitting diodes(micro-LEDs)with outstanding performance are promising candidates for next-generation displays.To achieve the application of high-resolution displays such as meta-displays,virtual reality,and wearable electronics,the size of LEDs must be reduced to the micro-scale.Thus,traditional technology cannot meet the demand during the processing of micro-LEDs.Recently,lasers with short-duration pulses have attracted attention because of their unique advantages during micro-LED processing such as noncontact processing,adjustable energy and speed of the laser beam,no cutting force acting on the devices,high efficiency,and low cost.Herein,we review the techniques and principles of laser-based technologies for micro-LED displays,including chip dicing,geometry shaping,annealing,laserassisted bonding,laser lift-off,defect detection,laser repair,mass transfer,and optimization of quantum dot color conversion films.Moreover,the future prospects and challenges of laser-based techniques for micro-LED displays are discussed.展开更多
Despite the application of conventional therapies,the prognosis of advanced gastric cancer(GC)or gastroesophageal junction cancer(GEJC)is still poor.In recent years,immune checkpoint inhibitors(ICIs)have reshaped the ...Despite the application of conventional therapies,the prognosis of advanced gastric cancer(GC)or gastroesophageal junction cancer(GEJC)is still poor.In recent years,immune checkpoint inhibitors(ICIs)have reshaped the paradigm of cancer therapy.Emerging evidence support the feasibility of programmed cell death-1(PD-1)and its ligand(PD-L1)inhibition in chemo-refractory GC/GEJC.Nivolumab and pembrolizumab have initially been approved in Japan and United States,respectively for the third-line treatment of progressive GC or GEJC.In March 2020,nivolumab has also been licensed in China for treating advanced GC/GEJC who received≥2 lines of systemic therapies.Current studies are moving forward to the first-line application or focusing on combination strategies,though data are insufficient and disputable.In this review,we summarize the recently reported and ongoing clinical trials in ICIs for advanced GC/GEJC.Molecular characteristics and clinical implications of different tumor subtypes are also reviewed.We further discuss the safety profile and biomarkers for predicting the response of ICIs,which has guiding values in clinical practice.展开更多
With the rapid development of 5G NR(New Radio),the explosive increment of traffic amount is calling the utilization of unlicensed band.3GPP has proposed LAA(Licensed Assisted Access)to use LTE in unlicensed band and p...With the rapid development of 5G NR(New Radio),the explosive increment of traffic amount is calling the utilization of unlicensed band.3GPP has proposed LAA(Licensed Assisted Access)to use LTE in unlicensed band and pointed out that NR-U(NR-Unlicensed)can reuse most designs of it.However,the existing channel access mechanism of LAA is conservative under the coexistence scenario of NR-U,which leads to the waste of time resource.To address the problem this paper proposes a hybrid channel access mechanism to take advantage of the LBT(Listen-Before-Talk)mechanism of LAA when channel is quite busy and transmit directly with reduced power when it is relatively idle.The channel busy degree is judged by a series of periodically updated adaptive thresholds.System-level simulation verifies that under the coexistence scenario of NR-U the proposed mechanism can achieve higher UPT(User Perceived Throughput)and lower delay than other channel access mechanisms.展开更多
基金supports from National Natural Science Foundation of China (62274138,11904302)Natural Science Foundation of Fujian Province of China (2023J06012)+2 种基金Science and Technology Plan Project in Fujian Province of China (2021H0011)Fujian Province Central Guidance Local Science and Technology Development Fund Project In 2022 (2022L3058)Compound semiconductor technology Collaborative Innovation Platform project of FuXiaQuan National Independent Innovation Demonstration Zone (3502ZCQXT2022005)。
文摘Micro-light-emitting diodes(micro-LEDs)with outstanding performance are promising candidates for next-generation displays.To achieve the application of high-resolution displays such as meta-displays,virtual reality,and wearable electronics,the size of LEDs must be reduced to the micro-scale.Thus,traditional technology cannot meet the demand during the processing of micro-LEDs.Recently,lasers with short-duration pulses have attracted attention because of their unique advantages during micro-LED processing such as noncontact processing,adjustable energy and speed of the laser beam,no cutting force acting on the devices,high efficiency,and low cost.Herein,we review the techniques and principles of laser-based technologies for micro-LED displays,including chip dicing,geometry shaping,annealing,laserassisted bonding,laser lift-off,defect detection,laser repair,mass transfer,and optimization of quantum dot color conversion films.Moreover,the future prospects and challenges of laser-based techniques for micro-LED displays are discussed.
基金the National Key Research and Development Program of China(No.2017YFC1308900)。
文摘Despite the application of conventional therapies,the prognosis of advanced gastric cancer(GC)or gastroesophageal junction cancer(GEJC)is still poor.In recent years,immune checkpoint inhibitors(ICIs)have reshaped the paradigm of cancer therapy.Emerging evidence support the feasibility of programmed cell death-1(PD-1)and its ligand(PD-L1)inhibition in chemo-refractory GC/GEJC.Nivolumab and pembrolizumab have initially been approved in Japan and United States,respectively for the third-line treatment of progressive GC or GEJC.In March 2020,nivolumab has also been licensed in China for treating advanced GC/GEJC who received≥2 lines of systemic therapies.Current studies are moving forward to the first-line application or focusing on combination strategies,though data are insufficient and disputable.In this review,we summarize the recently reported and ongoing clinical trials in ICIs for advanced GC/GEJC.Molecular characteristics and clinical implications of different tumor subtypes are also reviewed.We further discuss the safety profile and biomarkers for predicting the response of ICIs,which has guiding values in clinical practice.
基金the Project “Evaluation and verification of candidate solutions for international standardization of 5G” supported by National Science and Technology Major Project of the Ministry of Science and Technology (2018ZX03001024-006)
文摘With the rapid development of 5G NR(New Radio),the explosive increment of traffic amount is calling the utilization of unlicensed band.3GPP has proposed LAA(Licensed Assisted Access)to use LTE in unlicensed band and pointed out that NR-U(NR-Unlicensed)can reuse most designs of it.However,the existing channel access mechanism of LAA is conservative under the coexistence scenario of NR-U,which leads to the waste of time resource.To address the problem this paper proposes a hybrid channel access mechanism to take advantage of the LBT(Listen-Before-Talk)mechanism of LAA when channel is quite busy and transmit directly with reduced power when it is relatively idle.The channel busy degree is judged by a series of periodically updated adaptive thresholds.System-level simulation verifies that under the coexistence scenario of NR-U the proposed mechanism can achieve higher UPT(User Perceived Throughput)and lower delay than other channel access mechanisms.
